Severe viral pneumonia in adults: what is important for the ICU physician?

Gattarello, Simone; Rello, Jordi

doi:10.1080/21548331.2017.1345280

Cited by 6 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients often underwent mechanical ventilation with long ICU and hospital stays, associated with elevated health resource consumption. The results of this study agree with recent observations [13] suggesting a shift in the paradigm of severe pneumonia, recommending that viral infection (and specifically hMPV) should be ruled out when complicated with acute respiratory failure. While one out of four patients showed pneumococcal coinfection, plasma procalcitonin levels helped to implement antimicrobial stewardship.…”

Section: Resultssupporting

confidence: 91%

“…However, the presence of hMPV has been detected in 2–4% of adult patients admitted due to a community-acquired pneumonia (CAP) [8, 9] and has been associated with asthma and chronic obstructive pulmonary disease exacerbation [10–12]. The same as with other common respiratory viruses, hMPV is usually associated with non-severe pneumonia, whereas risk factors like immunosuppression, specific comorbidities—chronic lung disease, heart disease, blood disorders— elderly and living in long-term care facilities are associated with a higher risk of severe viral pneumonia [13, 14]. Nevertheless, recent studies suggest that hMPV infection is an underappreciated cause of critical illness, also in previously healthy patients [15–18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis

Vidaur

Totorika

Montes

et al. 2019

Ann. Intensive Care

Self Cite

View full text Add to dashboard Cite

Background Information on the clinical, epidemiological and molecular characterization of human metapneumovirus in critically ill adult patients with severe community-acquired pneumonia (CAP) and the role of biomarkers identifying bacterial coinfection is scarce. Methods This is a retrospective epidemiological study of adult patients with hMPV severe CAP admitted to ICU during a ten-year period with admission PSI score ≥ 3. Results The 92.8% of the 28 patients with severe CAP due to human metapneumovirus were detected during the first half of the year. Median age was 62 years and 60.7% were male. The genotyping of isolated human metapneumovirus showed group B predominance (60.7%). All patients had acute respiratory failure. Median APACHE II and SOFA score were 13 and 6.55, respectively. The 25% were coinfected with Streptococcus pneumoniae. 60.7% of the patients had shock at admission and 50% underwent mechanical ventilation. Seven patients developed ARDS, three of them younger than 60 years and without comorbidities. Mortality in ICU was 14.3%. Among survivors, ICU and hospital stay were 6.5 and 14 days, respectively. Plasma levels of procalcitonin were higher in patients with bacterial coinfection (18.2 vs 0.54; p < 0.05). The levels of C-reactive protein, however, were similar. Conclusion Human metapneumovirus was associated with severe CAP requiring ICU admission among elderly patients or patients with comorbidities, but also in healthy young subjects. These patients often underwent mechanical ventilation with elevated health resource consumption. While one out of four patients showed pneumococcal coinfection, plasma procalcitonin helped to implement antimicrobial stewardship. Electronic supplementary material The online version of this article (10.1186/s13613-019-0559-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis

Vidaur

Totorika

Montes

et al. 2019

Ann. Intensive Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…Viral pneumonia is a common respiratory tract infectious disease in children [ 1 ]. Due to the wide spread of pathogenic bacteria (such as droplets and direct contact), fast transmission, and sudden onset, it is prone to multisystem diseases complicating with the heart and brain in severe cases, seriously threatening the growth and development of children [ 2 , 3 ]. Respiratory syncytial virus pneumonia is common in infants and young children under the age of 2 and often presents with symptoms and signs such as wheezing, dyspnea, and pulmonary fine moist rales.…”

Section: Introductionmentioning

confidence: 99%

Clinical Observation of Reduning Combined with Recombinant Human Interferon α-2b in the Treatment of Children with Viral Pneumonia

Xie

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Purpose. To observe the clinical efficacy of Reduning injection combined with recombinant human interferon α-2b spray in the treatment of children with viral pneumonia. Methods. A total of 200 children with viral pneumonia over 2 years old who were admitted to the Pediatrics Department of the Cangzhou Central Hospital from September 2018 to November 2020 were recruited and randomized into the control group and observation group at a ratio of 1 : 1, with 100 cases in each group. The children in the control group were given recombinant human interferon α-2b spray, and the children in the observation group were given Reduning injection on the basis of the control group. The clinical symptoms and signs, clinical efficacy, levels of inflammatory mediators, and drug safety were compared between the two groups. Results. The t-test results showed that the disappearance time of body temperature, respiratory rate, pulmonary rales, and cough in the observation group was significantly shorter than that in the control group. The chi-square revealed a significantly higher total effective rate in the observation group vs. the control group. After treatment, the levels of IL-1, IL-6, TNF-α, and CRP in the two groups were lower than the corresponding values before treatment, and greater reduction was observed in the observation group in relative to the control group (both p < 0.05 ). The two groups have a similar safety profile. Conclusion. Reduning combined with recombinant human interferon α-2b produces a remarkable effect in the treatment of children with viral pneumonia, and it ameliorates clinical symptoms and reduces inflammatory response with a good safety profile.

show abstract

Neumonía viral grave en adultos

Delmotte,

Monsel

2024

EMC - Anestesia-Reanimación

View full text Add to dashboard Cite

Severe viral pneumonia in adults: what is important for the ICU physician?

Cited by 6 publications

References 38 publications

Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis

Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis

Clinical Observation of Reduning Combined with Recombinant Human Interferon α-2b in the Treatment of Children with Viral Pneumonia

Neumonía viral grave en adultos

Contact Info

Product

Resources

About